ABVC BioPharma (ABVC) News Today $0.52 +0.01 (+1.22%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period ABVC BioPharma believes ABV-1504 can fill void in market after ProzacDecember 20 at 8:04 PM | markets.businessinsider.comABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21December 19 at 9:42 AM | markets.businessinsider.comABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest UpdateDecember 13, 2024 | americanbankingnews.comABVC BioPharma receives $200,000 cash payment from OncoXDecember 12, 2024 | markets.businessinsider.comABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three PartnersDecember 11, 2024 | globenewswire.comABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational MilestonesNovember 14, 2024 | finance.yahoo.comRAKUS Co., Ltd. Reports Strong Growth in 2024November 14, 2024 | msn.comABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic PartnersOctober 22, 2024 | globenewswire.comABVC BioPharma (NASDAQ:ABVC) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic AchievementsAugust 15, 2024 | globenewswire.comABVC BioPharma's CEO Discusses New Drug Development and AI IntegrationJuly 19, 2024 | finance.yahoo.comImmunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50MMay 24, 2024 | finance.yahoo.comABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24MMay 22, 2024 | finance.yahoo.comABVC Stock Earnings: ABVC BioPharma Reported Results for Q1 2024May 17, 2024 | investorplace.comPromising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50MMay 15, 2024 | finance.yahoo.comCombination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MMay 9, 2024 | finance.yahoo.comABVC BioPharma, Inc. (ABVC)April 26, 2024 | finance.yahoo.comABVC BioPharma inks licensing deal for cancer drugApril 18, 2024 | investing.comABVC BioPharma, Inc.: AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareApril 18, 2024 | finanznachrichten.deAiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareApril 18, 2024 | globenewswire.comABVC BioPharma Enters Licensing Agreement With OncoX For Commercialization Of BLEX 404April 17, 2024 | markets.businessinsider.comABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MApril 17, 2024 | finance.yahoo.comABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MApril 17, 2024 | globenewswire.comABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50MApril 10, 2024 | globenewswire.comABVC BioPharma, Inc.: ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MMarch 28, 2024 | finanznachrichten.deWhy ABVC BioPharma Stock Is Up TodayMarch 27, 2024 | msn.comABVC Announces Global Licensing Deal With ForSeeCon Eye For VitargusMarch 26, 2024 | markets.businessinsider.comABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60MMarch 26, 2024 | globenewswire.comAiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million DollarsMarch 21, 2024 | finance.yahoo.comABVC BioPharma, Inc. (ABVC) Interactive Stock Chart - Yahoo FinanceMarch 19, 2024 | ca.finance.yahoo.comABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia MagazineMarch 19, 2024 | globenewswire.comABVC BioPharma, Inc.: ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateMarch 14, 2024 | finanznachrichten.deABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business UpdateMarch 14, 2024 | globenewswire.comABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion DollarsFebruary 27, 2024 | finance.yahoo.comABVC BioPharma, Inc.: ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 15, 2024 | finanznachrichten.deABVC Signes Agreement To License Its 'Know-How' To SPIFebruary 15, 2024 | markets.businessinsider.comABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 15, 2024 | finance.yahoo.comABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future RevenuesFebruary 15, 2024 | globenewswire.comABVC BioPharma, Inc.: ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)February 12, 2024 | finanznachrichten.deABVC BioPharma Receives Australian Patent For PDC-1421 For Treatment Of MDDFebruary 12, 2024 | markets.businessinsider.comABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)February 12, 2024 | finance.yahoo.comABVC BioPharma Conducts Private Equity and Warrants SaleFebruary 9, 2024 | msn.comABVC BioPharma Expands Footprint with Strategic Land AcquisitionsFebruary 9, 2024 | msn.comLooking Into ABVC BioPharma's Recent Short InterestJanuary 25, 2024 | benzinga.comABVC BioPharma files to sell 10.4M shares for holdersJanuary 12, 2024 | msn.comWhy Is Plant-Based Medications-Focused ABVC BioPharma Stock Trading Higher Today?January 3, 2024 | msn.comABVC BioPharma Reports Milestone Payment From From AiBtl BioPharma; AiBtl Becomes SubsidiaryJanuary 3, 2024 | markets.businessinsider.comABVC BioPharma Shares Jump 73% After Milestone PaymentJanuary 3, 2024 | marketwatch.comABVC Biopharma and unit receive $460M as first milestone payment; shares jumpJanuary 3, 2024 | msn.comABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical StudyDecember 7, 2023 | finance.yahoo.com Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Palantir in 2021, now we’re recommending this... (Ad)My research indicates there is only one investment that can meet AI's unprecedented demand for energy. Click to get the name and ticker symbol ABVC Media Mentions By Week ABVC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABVC News Sentiment▼0.440.59▲Average Medical News Sentiment ABVC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABVC Articles This Week▼20▲ABVC Articles Average Week Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Natural Alternatives International News Today Pluri News Today Enlivex Therapeutics News Today Senti Biosciences News Today Akari Therapeutics News Today Equillium News Today Calidi Biotherapeutics News Today Chemomab Therapeutics News Today Lakeshore Biopharma News Today MiNK Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABVC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
